Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of REST in the Alzheimer Disease Continuum (ERADC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03884023
Recruitment Status : Not yet recruiting
First Posted : March 21, 2019
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Jinzhou Tian, Dongzhimen Hospital, Beijing

Brief Summary:
The investigators assume that REST gene polymorphism affects REST protein concentration, and REST protein concentration in peripheral blood is related to cognitive function and hippocampus. In this current study, REST protein content and gene polymorphism will be obtained in peripheral blood in AD and normal control. The effect of REST gene polymorphism on REST protein concentration will be discovered.The relationship between REST protein concentration and cognitive function will be found, as well as the relationship between REST protein concentration and hippocampus.

Condition or disease
Alzheimer's Disease

Detailed Description:
Repressor element silencing transcription factor(REST), also known as neuron-restrictive silencer factor (NRSF) is a zinc finger protein of 121 kD and belongs to the Gli-Kruppel family with transcriptional regulation.This will be a Case-Crossover research. Consecutive participants will be divided into Alzheimer's disease dementia group, mild cognitive impairment due to Alzheimer's disease group and normal control group according to inclusion criteria of this research. Peripheral blood samples will be retained to detect REST gene polymorphisms and protein concentrations. Participants perform neuropsychological tests to assess cognitive function. Medial temporal atrophy scale is used to describe hippocampus. Differences in the mean or proportions between these 3 groups will be checked by t test or test. The relationship between REST protein concentration and cognitive function will be estimated, as well as the relationship between REST protein concentration and hippocampus.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Effect of REST on Cognitive Function and Hippocampus in the Alzheimer Disease Continuum
Estimated Study Start Date : June 28, 2019
Estimated Primary Completion Date : November 30, 2019
Estimated Study Completion Date : February 12, 2020


Group/Cohort
AD group
Alzheimer's disease
aMCI group
Amnestic Mild Cognitive(MCI) impairment due to Alzheimer's disease
NC group
Normal Control



Primary Outcome Measures :
  1. Rate of Gene polymorphism in rs2227902 and rs3796529. [ Time Frame: baseline ]
    Verifying the value of REST gene polymorphism as an early markers of Alzheimer's Disease

  2. Concentration of REST protein [ Time Frame: baseline ]
    Verifying the value of REST protein detection as an early markers of Alzheimer's Disease


Biospecimen Retention:   Samples With DNA
Peripheral Blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The study population include Alzheimer's disease patients ,patients with amnestic mild cognitive impairment, and normal subjects who meet the inclusion and exclusion criteria and signed the informed consent in this study,and they will be recruited form outpatients, inpatients of Dongzhimen hospital and community.
Criteria

1. Inclusion Criteria of Normal Control (NC):

  1. No active neurological and mental illness;
  2. No use of psychotropic drugs;
  3. Patients may have diseases, but these diseases and their treatment have no effect on cognition (MMSE>28);
  4. Single cognitive field test was normal;
  5. The clinical dementia rating scale is normal (CDR=0);
  6. Aged 55-85, male or female;
  7. Sufficient vision and hearing for neuropsychological tests;
  8. Have a certain level of education, can read and write simple sentences;
  9. Sign the informed consent.

2. Inclusion Criteria of AD-induced MCI (aMCI):

  1. Complained of memory loss or/and confirmed by others;
  2. Objective evidence suggests memory impairment (DSR<12.5 or HVLT<18.5, adjusted for age);
  3. Preservation of overall cognitive function (MMSE 24-30/30, corrected according to education);
  4. Most of daily life activities are reserved (ADL<16/56);
  5. No dementia (CDR ≤0.5), and memory score was 0.5 or 1point;
  6. Visual score of medial temporal atrophy (MTA) in MRI is greater than or equal to 0.5 or 1.0 point, which shall be corrected according to age);
  7. Aged 55-85, male or female;
  8. Sufficient vision and hearing for neuropsychological tests;
  9. Sign the informed consent.

3. Exclusion Criteria of MCI due to AD:

  1. Meet the DSM-IV diagnostic criteria of dementia;
  2. Obvious cerebrovascular diseases in MRI;
  3. Depression or other mental illnesses that meet the DSM-IV criteria in the past 2 years, the simplified version of the Geriatric Depression Scale (GDS-15) ≥ 8 ;
  4. A history of alcohol or substance abuse or addiction in the past 2 years;
  5. History of schizophrenia;
  6. Any obvious neurological diseases, such as Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumors, progressive supra nuclear paralysis, epilepsy, chronic subdural hematoma, multiple sclerosis, severe head trauma with persistent neurological impairment or known structural brain abnormalities;
  7. In investigator's impression, the subject cannot cooperate with the research procedure;
  8. Other known systemic diseases that cause dementia (such as hypothyroidism, folate or vitamin B deficiency, neurosyphilis, HIV infection).

4. Inclusion Criteria for AD:

  1. An insidious onset of disease in which symptoms develop gradually over months or years rather than suddenly over hours or days;
  2. Definite history of cognitive deterioration was reported or observed;
  3. Objective evidence suggests that at least one cognitive domain decline (e.g., DSR<9.5 or HVLT<18.5, adjusted for age);
  4. Decrease in overall cognitive function (MMSE≤26, adjusted for education);
  5. Decreased in ability of daily life: ADL≥16;
  6. Dementia (CDR≥0.5), and memory score≥ 0.5;
  7. Visual score of medial temporal atrophy in MRI (MTA) is greater than or equal to 0.5 or 1.0 point, adjusted for age);
  8. Aged 55-85, male or female;
  9. Sufficient vision and hearing for neuropsychological tests;
  10. Sign the informed consent.

5. Exclusion Criteria for AD :

  1. With severe cerebrovascular disease, defined as a history of stroke temporal associated with the occurrence or deterioration of cognitive impairment; Or the occurrence of multiple or severe infarction or severe white matter high signal;
  2. Have the core characteristics of Lewy body dementia rather than dementia itself;
  3. Significant characteristics of frontotemporal dementia with behavioral variation;
  4. Significant characteristics of primary progressive semantic aphasia or primary progressive non-fluency/grammatical confusion aphasia;
  5. Evidence of other complications of active neurological diseases, or non-neurological complications, or serious cognitive effects of drug use;
  6. Depression or other mental illnesses that meet the DSM-IV criteria in the past 2 years, the simplified version of the Geriatric Depression Scale (GDS-15) ≥ 8 points;
  7. Other known systemic diseases that cause dementia (such as hypothyroidism, folate or vitamin B deficiency, neurosyphilis, HIV infection).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03884023


Contacts
Layout table for location contacts
Contact: Tian Jinzhou, MD,PhD 861084013229 ext 861084013229 jztian@hotmail.com
Contact: Shi Jing, MD,PhD 861084013229 ext 861084013229 shijing87@hotmail.com

Locations
Layout table for location information
China, Beijing
Dongzhimen Hospital,Beijing University of Chinese Medicine
Beijing, Beijing, China, 100700
Sponsors and Collaborators
Dongzhimen Hospital, Beijing
Investigators
Layout table for investigator information
Principal Investigator: Tian Jinzhou, MD,PhD Dongzhimen Hospital,Beijing University of Chinese Medicine
Layout table for additonal information
Responsible Party: Jinzhou Tian, Clinical Professor, Dongzhimen Hospital, Beijing
ClinicalTrials.gov Identifier: NCT03884023    
Other Study ID Numbers: DZMEC-KY-2019-11
First Posted: March 21, 2019    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jinzhou Tian, Dongzhimen Hospital, Beijing:
Plasma REST
REST gene polymorphism
AD
Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders